[Skip to Content]
[Skip to Content Landing]
Views 336
Citations 0
Comment & Response
June 12, 2019

Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment?

Author Affiliations
  • 1Department of Physiology, Amsterdam University Medical Center, location VUmc, Amsterdam, the Netherlands
JAMA Cardiol. 2019;4(8):831-832. doi:10.1001/jamacardio.2019.1752

To the Editor We congratulate Coats et al1 for their report on the randomized clinical trial of trimetazidine, a direct β-oxidation inhibitor, in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Current therapies for HCM are insufficient, and the search for disease-modifying treatments must be continued. The trimetazidine trial is one of few clinical trials in HCM thus far, to our knowledge. We would like to highlight aspects that may have contributed to the negative outcome of the reported trial.

×